References
- Tomblyn, M.R. and Tallman, M.S. (2003) "New developments in antibody therapy for acute myeloid leukemia", Semin. Oncol., 30(4), 502— 508.
- Dinndorf, P.A., Andrews, R.G., Benjamin, D., Ridgway, D., Wolff, L. and Bernstein, I.D. (1986) "Expression of normal myeloid-associated antigens by acute leukemia cells", Blood, 67(4), 1048 — 1053.
- Jilani, I., Estey, E., Huh, Y., Joe, Y., Manshouri, T., Yared, M., et al. (2002) "Differences in CD33 intensity between various myeloid neoplasms", Am. J. Clin. Pathol., 118(4), 560— 566.
- Hamann, P.R., Hinman, L.M., Hollander, I., Beyer, C.F., Lindh, D., Holcomb, R., et al. (2002) "Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia", Bioconjug. Chem., 13(1), 47 — 58.
- Zein, N., Poncin, M., Nilakantan, R. and Ellestad, G.A. (1989) "Calicheamicin gamma II and DNA: molecular recognition process responsible for site-specificity", Science, 244(4905), 697–699.
- Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., Forman, Si., Flowers, D., Smith, F.O., et al. (1999) "Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate", Blood, 93(11), 3678–3684.
- Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Low-enberg, B., Dombret, H., et al. (2001) "Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse", J. Clin. Oncol., 19(13), 3244 — 3254.
- Larson, R.A., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E.A., Sievers, E.L., et al. (2002) "Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)", Leukemia, 16(9), 1627 — 1636.
- Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., et al. (2001) "Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia", Clin. Cancer Res., 7(6), 1490 — 1496.
- Piccaluga, P., Martinelli, G., Rondoni, M., Malagola, M., Ronconi, S., Visani, G., et al. (2003) "Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly", Haematologica, 88(12), ECR37.
- Saviola, A., Luppi, M., Potenza, L., Morselli, M., Ferrari, A., Riva, G., et al. (2003) "Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide", Br. J. Haematol., 123(4), 752–753.
- Roboz, G.J., Knovich, M.A., Bayer, R.L., Schuster, M.W., Seiter, K., Powell, B.L., et al. (2002) "Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leuke-mia", Leuk. Lymphoma, 43(10), 1951–1955.
- Giles, F.J., Kantarjian, H.M., Kornblau, S.M., Thomas, D.A., Garcia-Manero, G., Waddelow, T.A., et al. (2001) "Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation", Cancer, 92(2), 406–413.
- Rajvanshi, P., Shulman, H.M., Sievers, E.L. and McDonald, G.B. (2002) "Hepatic sinusoidal obstruction after gemtuzumab ozoga-micin (Mylotarg) therapy", Blood, 99(7), 2310–2314.
- Walter, R.B., Raden, B.W., Hong, T.C., Flowers, D.A., Bernstein, I.D. and Linenberger, M.L. (2003) "Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells", Blood, 102(4), 1466–1473.
- Kell, W.J., Burnett, AK., Chopra, R., Yin, J.A., Clark, RE., Rohatiner, A., et al. (2003) "A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive che-motherapy in induction and consolidation in younger patients with acute myeloid leukemia", Blood, 102(13), 4277–4283.